查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613020

全球丛集性头痛市场（按丛集性头痛类型、药物类型、给药途径和分销管道）：未来预测（2025-2030）

Cluster Headache Market by Cluster Headaches Type, Drug Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，丛集性头痛市场价值为3.8104亿美元，预计到2024年将达到4.018亿美元，复合年增长率为5.71%，到2030年将达到5.6238亿美元。

丛集性头痛是一种神经系统疾病，其特征是头部一侧（通常是眼睛周围）反覆发作剧烈疼痛。丛集性头痛的研究和市场分析范围包括了解有效治疗的需求、医疗实践中的应用以及主要包括製药公司、医疗保健提供者和患者的最终用途范围。这种疾病的盛行率不断上升及其对患者生活品质的破坏性影响推动了对治疗解决方案的需求。影响市场成长的主要因素包括神经学研究的进步、意识的提高以及医疗基础设施的改善。在正在进行的临床试验和监管核准的推动下，非侵入性神经刺激疗法和新颖配方等创新疗法正在提供新的商机。然而，新治疗方法的高成本、新兴市场的患者获取机会有限以及准确诊断这种罕见疾病的复杂性等挑战构成了巨大的市场障碍。为了利用潜在的机会，相关人员应专注于与生物技术公司和研究机构合作，加速研究和开发，投资于公众意识宣传活动，并透过学名药开发提高可及性。此外，透过集中精力进行个人化医疗和寻找与丛集性头痛相关的遗传倾向，可以发现开拓的市场潜力。虽然技术创新目前集中在标靶药物疗法和技术整合上，但对生活方式改变和综合疗法等非药物干预措施的更深入探索有可能使治疗管道多样化。竞争格局仍适度集中，GlaxoSmithKline Plc等大型製药企业与新兴生技公司竞争。最终，在未满足的临床需求和不断发展的治疗范式的推动下，未满足的关键字市场将会成长，但必须克服经济和教育方面的限制，以实现公平的市场扩张。

主要市场统计
基准年[2023] 38104万美元
预计年份 [2024] 4.018 亿美元
预测年份 [2030] 56238万美元
复合年增长率（%） 5.71%

市场动态：揭示快速发展的丛集性头痛市场的关键市场洞察

供需的动态交互作用正在改变丛集性头痛市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球丛集性头痛盛行率上升
    • 药品和医疗技术领域的持续研究和开发倡议
    • 医疗投入快速增加扩大治疗选择
  • 市场限制因素
    • 对丛集性头痛缺乏认识或误诊
  • 市场机会
    • 针对每位患者基因量身定制的个人化医疗的进展
    • 新开发的丛集性头痛药物继续产品核可
  • 市场挑战
    • 产品核可的复杂监理要求

波特五力：驾驭集群性头痛市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解丛集性头痛市场的外部影响

外部宏观环境因素在塑造丛集性头痛市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解丛集性头痛市场的竞争格局

对丛集性头痛市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：集群头痛市场供应商绩效评估

FPNV定位矩阵是评估集群头痛市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製丛集性头痛市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对丛集性头痛市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析最近的产品发布、开拓的地区、关键产业进展以及塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1. 目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3. 塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 哪些收益来源和策略机会推动供应商的进入/退出策略？

目录

第一章简介

第二章 分析方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球丛集性头痛盛行率增加
      • 持续致力于药品和医疗技术的研究和开发
      • 医疗投入快速增加，扩大治疗选择
    • 抑制因素
      • 对丛集性头痛缺乏认识或误诊
    • 机会
      • 针对每位患者基因量身定制的个人化医疗的进展
      • 新开发的丛集性头痛药物的产品核可正在进行中
    • 任务
      • 产品核可的复杂监理要求
  • 市场区隔分析
    • 丛集性头痛的类型：丛集性头痛增加了治疗慢性头痛的药物需求
    • 分销管道：网路药局越来越受到有效产品渗透的青睐
  • 波特五力分析
  • PESTEL分析
    • 政治因素
    • 经济因素
    • 社会因素
    • 技术因素
    • 法律因素
    • 环境因素

第六章 丛集性头痛市场：按丛集性头痛类型

  • 慢性丛集性头痛
  • 阵发性丛集性头痛

第七章丛集性头痛市场：依药物类型

  • 抗癫痫药
  • 钙离子通道阻断剂
  • 皮质类固醇
  • 麦角
  • 碳酸锂
  • 褪黑素
  • Sumatriptan

第八章丛集性头痛市场：依给药途径

  • 静脉
  • 口服
  • 局部的

第 9 章 丛集性头痛市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第十章 北美和南美丛集性头痛市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太集群性头痛市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲丛集性头痛市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • 安进透过策略收购 Horizo​​n Therapeutics 扩大治疗产品组合
    • Tonics Pharmaceuticals 透过策略性收购扩大偏头痛治疗产品组合
    • FDA核准QULIPTA 用于治疗慢性和阵发性偏头痛
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • electroCore, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Lundbeck LLC
  • Lupin Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-CA100284D080

The Cluster Headache Market was valued at USD 381.04 million in 2023, expected to reach USD 401.80 million in 2024, and is projected to grow at a CAGR of 5.71%, to USD 562.38 million by 2030.

Cluster headaches are a neurological disorder characterized by severe, recurring pain in one side of the head, often around the eye. The scope of research and market analysis on cluster headaches involves understanding the necessity of effective treatments, their application in medical practice, and their end-use scope, which primarily includes pharmaceutical companies, healthcare providers, and patients. The demand for treatment solutions is driven by the rising prevalence of the disorder and the debilitating impact on patient quality of life. Key factors influencing market growth include advancements in neurological research, increasing awareness, and improving healthcare infrastructure. Innovative treatments like non-invasive neurostimulation and novel pharmaceutical formulations present emerging opportunities, driven by ongoing clinical trials and regulatory approvals. However, challenges such as high costs of novel treatments, limited patient access in developing regions, and the complexity of accurately diagnosing this rare condition pose significant market barriers. To harness potential opportunities, stakeholders should focus on partnerships between biotech firms and research institutions to accelerate R&D, investing in public awareness campaigns, and expanding accessibility through generic drug development. A concentrated effort on personalized medicine and exploring the genetic predispositions associated with cluster headaches may also unlock unexplored market potentials. While innovation is currently directed towards targeted drug therapies and technological integration, a deeper exploration into non-pharmaceutical interventions, such as lifestyle modifications and integrative therapies, could diversify treatment pipelines. The competitive landscape remains moderately concentrated, with established pharmaceutical giants, like GlaxoSmithKline, vying against emerging biotech firms. Ultimately, the cluster headache market is poised for growth, driven by unmet clinical needs and evolving treatment paradigms, but overcoming economic and educational constraints remains crucial for achieving equitable market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 381.04 million
Estimated Year [2024] USD 401.80 million
Forecast Year [2030] USD 562.38 million
CAGR (%) 5.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cluster Headache Market

The Cluster Headache Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cluster headaches worldwide
    • Ongoing research and development initiatives in pharmaceuticals and medical technology
    • Surging healthcare investments to advance treatment options
  • Market Restraints
    • Low awareness or misdiagnosis of cluster headaches
  • Market Opportunities
    • Advancements in personalized medicines tailored to individual patient genetics
    • Ongoing product approvals for newly developed cluster headache drugs
  • Market Challenges
    • Complex regulatory requirements for product approvals

Porter's Five Forces: A Strategic Tool for Navigating the Cluster Headache Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cluster Headache Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cluster Headache Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cluster Headache Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cluster Headache Market

A detailed market share analysis in the Cluster Headache Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cluster Headache Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cluster Headache Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cluster Headache Market

A strategic analysis of the Cluster Headache Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cluster Headache Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen, Inc., Boehringer Ingelheim International GmbH, electroCore, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Lundbeck LLC, Lupin Limited, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cluster Headache Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cluster Headaches Type, market is studied across Chronic Cluster Headaches and Episodic Cluster Headaches.
  • Based on Drug Type, market is studied across Anti-Seizure Drugs, Calcium Channel Blockers, Corticosteroids, Ergots, Lithium carbonate, Melatonin, and Sumatriptan.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cluster headaches worldwide
      • 5.1.1.2. Ongoing research and development initiatives in pharmaceuticals and medical technology
      • 5.1.1.3. Surging healthcare investments to advance treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Low awareness or misdiagnosis of cluster headaches
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in personalized medicines tailored to individual patient genetics
      • 5.1.3.2. Ongoing product approvals for newly developed cluster headache drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory requirements for product approvals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cluster Headaches Type: Increasing need for drugs to treat chronic cluster headache
    • 5.2.2. Distribution Channel: Rising preference for online pharmacies for effective product penetration
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cluster Headache Market, by Cluster Headaches Type

  • 6.1. Introduction
  • 6.2. Chronic Cluster Headaches
  • 6.3. Episodic Cluster Headaches

7. Cluster Headache Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Anti-Seizure Drugs
  • 7.3. Calcium Channel Blockers
  • 7.4. Corticosteroids
  • 7.5. Ergots
  • 7.6. Lithium carbonate
  • 7.7. Melatonin
  • 7.8. Sumatriptan

8. Cluster Headache Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Topical

9. Cluster Headache Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Cluster Headache Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cluster Headache Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cluster Headache Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Amgen Expands Therapeutic Portfolio Through Strategic Acquisition of Horizon Therapeutics
    • 13.3.2. Tonix Pharmaceuticals Expands Migraine Treatment Portfolio with Strategic Acquisition
    • 13.3.3. FDA Approval of QULIPTA for Treatment of Chronic and Episodic Migraine
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca plc
  • 4. Biogen, Inc.
  • 5. Boehringer Ingelheim International GmbH
  • 6. electroCore, Inc.
  • 7. Eli Lilly and Company
  • 8. GlaxoSmithKline PLC
  • 9. Lundbeck LLC
  • 10. Lupin Limited
  • 11. Pfizer Inc.
  • 12. Sun Pharmaceutical Industries Ltd.
  • 13. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CLUSTER HEADACHE MARKET RESEARCH PROCESS
  • FIGURE 2. CLUSTER HEADACHE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CLUSTER HEADACHE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CLUSTER HEADACHE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLUSTER HEADACHE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CLUSTER HEADACHE MARKET DYNAMICS
  • TABLE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CHRONIC CLUSTER HEADACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY EPISODIC CLUSTER HEADACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-SEIZURE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERGOTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY LITHIUM CARBONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY MELATONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. CLUSTER HEADACHE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. CLUSTER HEADACHE MARKET, FPNV POSITIONING MATRIX, 2023